SI2651398T1 - SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS - Google Patents

SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS Download PDF

Info

Publication number
SI2651398T1
SI2651398T1 SI201131427T SI201131427T SI2651398T1 SI 2651398 T1 SI2651398 T1 SI 2651398T1 SI 201131427 T SI201131427 T SI 201131427T SI 201131427 T SI201131427 T SI 201131427T SI 2651398 T1 SI2651398 T1 SI 2651398T1
Authority
SI
Slovenia
Prior art keywords
mmol
amino
hydroxybenzoyl
agonist
glp
Prior art date
Application number
SI201131427T
Other languages
English (en)
Slovenian (sl)
Inventor
Per Sauerberg
Simon Bjerregaard
Flemming Seier Nielsen
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43903993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2651398(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of SI2651398T1 publication Critical patent/SI2651398T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
SI201131427T 2010-12-16 2011-12-16 SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS SI2651398T1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP10195285 2010-12-16
US201061425087P 2010-12-20 2010-12-20
PCT/EP2011/073060 WO2012080471A1 (en) 2010-12-16 2011-12-16 Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
EP11805824.7A EP2651398B1 (en) 2010-12-16 2011-12-16 Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid

Publications (1)

Publication Number Publication Date
SI2651398T1 true SI2651398T1 (en) 2018-04-30

Family

ID=43903993

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201131427T SI2651398T1 (en) 2010-12-16 2011-12-16 SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS
SI201131885T SI3326620T1 (sl) 2010-12-16 2011-12-16 Trdne sestave, ki vsebujejo agonist GLP-1 in sol N-(8-(2-hidroksibenzoil)amino)kaprilne kisline

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI201131885T SI3326620T1 (sl) 2010-12-16 2011-12-16 Trdne sestave, ki vsebujejo agonist GLP-1 in sol N-(8-(2-hidroksibenzoil)amino)kaprilne kisline

Country Status (21)

Country Link
US (7) US9278123B2 (enExample)
EP (3) EP3326620B1 (enExample)
JP (2) JP5902194B2 (enExample)
KR (1) KR101925620B1 (enExample)
CN (2) CN103260608A (enExample)
AU (1) AU2011343190B2 (enExample)
BR (1) BR112013014942B1 (enExample)
CA (1) CA2821886A1 (enExample)
DK (2) DK3326620T3 (enExample)
ES (1) ES2661676T3 (enExample)
HR (1) HRP20180425T1 (enExample)
HU (1) HUE036066T2 (enExample)
LT (1) LT2651398T (enExample)
MX (2) MX345501B (enExample)
PL (2) PL3326620T3 (enExample)
PT (1) PT2651398T (enExample)
RS (2) RS56998B1 (enExample)
RU (1) RU2600440C3 (enExample)
SI (2) SI2651398T1 (enExample)
SM (1) SMT201800117T1 (enExample)
WO (1) WO2012080471A1 (enExample)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2600440C3 (ru) 2010-12-16 2021-12-10 Ново Нордиск А/С Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
KR101972836B1 (ko) 2011-04-12 2019-04-29 노보 노르디스크 에이/에스 이중 아실화된 ｇｌｐ-1 유도체
EP2827845B1 (en) 2012-03-22 2018-12-26 Novo Nordisk A/S Compositions comprising a delivery agent and preparation thereof
ES2715308T3 (es) * 2012-03-22 2019-06-03 Novo Nordisk As Composiciones que comprenden un agente de suministro y su preparación
HUE062740T2 (hu) * 2012-03-22 2023-12-28 Novo Nordisk As GLP-1 peptidek készítményei és elõállításuk
JP6517690B2 (ja) * 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
PL2866825T3 (pl) 2012-07-01 2021-02-22 Novo Nordisk A/S <div>ZASTOSOWANIE PEPTYDÓW GLP-1 O PRZEDŁUŻONYM DZIAŁANIU</div>
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
MX2015008077A (es) 2012-12-21 2015-10-30 Sanofi Sa Derivados de exendina-4 como agonistas dobles de glp1/gip o trigonal de glp1-gip/glucagon.
DK2964193T3 (da) 2013-03-05 2020-03-16 Enteris Biopharma Inc Lægemidler til oral indgivelse
CN104055735B (zh) * 2013-03-22 2016-08-03 深圳翰宇药业股份有限公司 一种萨摩鲁泰的脂质体及其制备方法
CA2910903A1 (en) 2013-05-02 2014-11-06 Novo Nordisk A/S Oral dosing of glp-1 compounds
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
DK3006045T3 (en) * 2014-10-07 2017-07-17 Cyprumed Gmbh Pharmaceutical formulations for oral administration of peptide or protein drugs
CN105777872B (zh) * 2014-12-16 2019-06-07 深圳翰宇药业股份有限公司 一种萨摩鲁肽的纯化方法
JP6910950B2 (ja) 2015-01-12 2021-07-28 エンテリス・バイオファーマ・インコーポレイテッドＥｎｔｅｒｉｓ Ｂｉｏｐｈａｒｍａ，Ｉｎｃ． 固形経口剤形
CN107205948B (zh) * 2015-01-29 2021-12-14 诺和诺德股份有限公司 包含glp-1激动剂和肠溶衣的片剂
WO2016128972A1 (en) 2015-02-09 2016-08-18 Entera Bio Ltd. Formulations for oral administration of active agents with controlled absorption profile
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
WO2017149070A1 (en) 2016-03-03 2017-09-08 Novo Nordisk A/S Glp-1 derivatives and uses thereof
BR112018072020A2 (pt) * 2016-04-28 2019-02-12 Novo Nordisk A/S semaglutida em condições cardiovasculares
IL312218B2 (en) 2016-08-17 2025-11-01 Entera Bio Ltd Formulations for oral administration of active agents
JOP20190060A1 (ar) 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
US11166939B2 (en) 2017-04-25 2021-11-09 Otsuka Pharmaceutical Co. Ltd Lisinopril compositions with an ingestible event marker
TWI797133B (zh) * 2017-06-09 2023-04-01 丹麥商諾佛 儂迪克股份有限公司 用於經口投予的固體組成物
WO2019004088A1 (ja) 2017-06-27 2019-01-03 株式会社バイオセレンタック 粘膜付着性経口製剤
CN111050750B (zh) 2017-08-24 2024-09-24 诺和诺德股份有限公司 Glp-1组合物及其用途
MY204827A (en) 2017-10-12 2024-09-18 Novo Nordisk As Semaglutide in medical therapy
EP4299118A3 (en) 2018-02-02 2024-04-10 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
PE20211492A1 (es) 2018-10-26 2021-08-11 Novo Nordisk As Composiciones estables de semaglutida y usos de las mismas
WO2020152304A1 (en) 2019-01-24 2020-07-30 Novo Nordisk A/S Roller compactor and method of dry granulation using a roller compactor
WO2020180534A1 (en) 2019-03-01 2020-09-10 President And Fellows Of Harvard College Methods and compositions for protein delivery
CN113677336B (zh) 2019-04-10 2024-04-30 基恩菲特公司 包含式(i)化合物和glp-1受体激动剂的组合疗法
JP2022543826A (ja) * 2019-08-07 2022-10-14 ノヴォ ノルディスク アー／エス Ｐｙｙ化合物とｎ－（８－（２－ヒドロキシベンゾイル）アミノ）カプリル酸の塩とを含む固形組成物
CA3144618A1 (en) 2019-08-07 2021-02-11 Novo Nordisk A/S Solid compositions comprising an egf(a) derivative and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
JP7767264B2 (ja) * 2019-09-02 2025-11-11 ノヴォ ノルディスク アー／エス Ｇｌｐ－１ペプチドを含む錠剤を生成するためのプロセス
ES3006288T3 (en) * 2019-09-06 2025-03-18 Novo Nordisk As Method and equipment for fractionation of granules for use in pharmaceutical compositions
JP7670698B2 (ja) * 2019-11-06 2025-04-30 ノヴォ ノルディスク アー／エス 認知症におけるｇｌｐ－１受容体作動薬
AU2020378624A1 (en) 2019-11-07 2022-04-21 Novo Nordisk A/S Solid compositions comprising a PCSK9 inhibitor and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
EP4054536A1 (en) 2019-11-07 2022-09-14 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
US20230165939A1 (en) * 2020-04-29 2023-06-01 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and histidine
EP4663197A2 (en) 2020-05-29 2025-12-17 Sciwind Biosciences Co., Ltd. N-[8-(2-hydroxybenzoyl)amino]potassium octanoate crystal polymorph, and preparation method therefor and use thereof
CN113735734B (zh) * 2020-05-29 2023-12-08 杭州先为达生物科技股份有限公司 N-[8-(2-羟基苯甲酰基)氨基]辛酸钾晶体多晶型物及其制备方法和用途
TW202315883A (zh) 2020-07-22 2023-04-16 丹麥商諾佛 儂迪克股份有限公司 適用於口服的glp-1及gip受體共促效劑
CN112274633B (zh) * 2020-09-16 2023-11-07 广州新济薇娜生物科技有限公司 索马鲁肽降糖减重微针贴片及其制备方法和应用
CN112062690A (zh) * 2020-11-11 2020-12-11 北京先为达生物科技有限公司 N-[8-(2-羟基苯甲酰基)氨基]辛酸钾晶体多晶型物及其制备方法和用途
CR20230308A (es) 2020-12-11 2023-09-08 Civi Biopharma Inc Entrega oral de conjugados antisentido que tienen por blanco a pcsk9
TWI850611B (zh) 2020-12-18 2024-08-01 丹麥商諾佛 儂迪克股份有限公司 Glp-1及澱粉素受體之共促效劑
FR3120189B1 (fr) 2021-03-01 2024-11-29 Farid Bennis Composition pharmaceutique pour une administration par voie orale d’un agoniste du récepteur du GLP-1
WO2022202864A1 (ja) 2021-03-24 2022-09-29 塩野義製薬株式会社 縮合環を有するｇｌｐ－１受容体作動薬を含有する医薬組成物
US11667614B2 (en) 2021-04-16 2023-06-06 Navinta III Inc. Process for the preparation of highly pure Salcaprozic Acid and pharmaceutically acceptable salts thereof
WO2022221629A1 (en) 2021-04-16 2022-10-20 Navinta Iii Inc Process for the preparation of highly pure salcaprozic acid and pharmaceutically acceptable salts thereof
WO2022226217A1 (en) 2021-04-22 2022-10-27 Civi Biopharma, Inc. Oral delivery of oligonucleotides
WO2022268213A1 (zh) * 2021-06-25 2022-12-29 甘李药业股份有限公司 含glp-1化合物的药物组合物
MX2024000768A (es) 2021-07-15 2024-02-12 Novo Nordisk As Comprimido que comprende una sal del acido n-(8-(2-hidroxibenzoil) amino)caprilico.
CN117916221A (zh) 2021-07-16 2024-04-19 诺和诺德股份有限公司 N-(8-(2-羟基苯甲酰基)氨基)辛酸钠多晶型形式a
US20230053812A1 (en) * 2021-07-27 2023-02-23 Aurobindo Pharma Ltd Stable peptide formulations for oral use
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations
WO2023065231A1 (en) * 2021-10-21 2023-04-27 Guangzhou Dazhou Biomedicine Ltd. Oral delivery of therapeutic agents
MX2024005705A (es) 2021-11-10 2024-05-24 I2O Therapeutics Inc Composiciones de liquidos ionicos.
EP4180060A1 (en) * 2021-11-15 2023-05-17 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4299057A1 (en) * 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
CA3251864A1 (en) * 2022-02-24 2023-08-31 Entera Bio Ltd. Formulations comprising an acid-neutralizing polymer for the oral administration of a glucagon-type peptide-1 and its analogues
WO2023179796A1 (en) * 2022-03-25 2023-09-28 Beijing Ql Biopharmaceutical Co., Ltd. Pharmaceutical compositions of polypeptide conjugates and methods of uses thereof
WO2024017139A1 (zh) * 2022-07-20 2024-01-25 成都海博为药业有限公司 一种含有glp-1受体激动剂类似物的药物组合物
JPWO2024063143A1 (enExample) 2022-09-22 2024-03-28
TW202421645A (zh) 2022-11-25 2024-06-01 丹麥商諾佛 儂迪克股份有限公司 如ｇｌｐ—１之肽治療劑的口服投與
CN121001710A (zh) 2022-12-30 2025-11-21 阿尔吉法玛公司 提高口服多肽治疗剂的全身生物利用度的组合物和方法
WO2025017454A1 (en) * 2023-07-14 2025-01-23 Biophore India Pharmaceuticals Pvt. Ltd Stable solid dispersions of salcaprozate with various active pharmaceutical ingredients
TW202540155A (zh) 2023-11-30 2025-10-16 丹麥商諾佛 儂迪克股份有限公司 Glp-1、gip及澱粉素受體之三重促效劑
US20250326814A1 (en) 2024-02-06 2025-10-23 Opko Biologics Ltd. Modified oxyntomodulin and methods of use thereof
WO2025220032A1 (en) * 2024-04-16 2025-10-23 Bhami's Research Laboratory, Pvt. Ltd. Polypeptide formulations for oral delivery
CN118319871B (zh) * 2024-04-19 2025-08-05 鲁南新时代生物技术有限公司 一种司美格鲁肽药物组合物
AU2024204465A1 (en) * 2024-06-28 2026-01-15 Merdury Biopharmaceutical Corporation Oral peptide drug structure and manufacturing method thereof
WO2026017601A1 (en) 2024-07-15 2026-01-22 F. Hoffmann-La Roche Ag Novel formulations for oral administration of oligonucleotides

Family Cites Families (192)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR8701121A (pt) 1986-03-12 1988-01-05 Glaxo Group Ltd Processo para a preparacao de um composto e processo para combate a pestes
EP0512042B1 (en) 1990-01-24 1998-04-08 BUCKLEY, Douglas I. Glp-1 analogs useful for diabetes treatment
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
HUT73494A (en) 1993-03-29 1996-08-28 Univ Cincinnati Analogs of peptide yy and uses thereof
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
EP0803255A4 (en) 1994-06-03 1999-06-30 Tsumura & Co MEDICINAL COMPOSITION
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5574010A (en) 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
BR9604880A (pt) 1995-03-31 1998-05-19 Emisphere Tech Inc Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
CA2264243C (en) 1996-08-30 2004-10-05 Novo Nordisk A/S Glp-1 derivatives
ES2290799T3 (es) 1996-11-12 2008-02-16 Novo Nordisk A/S Uso de peptidos glp-1.
JP2000505105A (ja) 1996-11-13 2000-04-25 ユニヴァーシティ・オブ・シンシナティ ペプチドｙｙのアナログおよびその使用
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
EP0908515A3 (en) 1997-09-16 2000-04-26 Smithkline Beecham Plc Pancreatic polypeptide
EP1062240B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S N-terminally modified glp-1 derivatives
WO1999043341A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
JP2002508162A (ja) 1998-02-27 2002-03-19 ノボ ノルディスク アクティーゼルスカブ Ｎ末端を短縮したｇｌｐ−１誘導体
AU2610699A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Derivatives of glp-1 analogs
WO1999043708A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
US6046167A (en) 1998-03-25 2000-04-04 University Of Cincinnati Peptide YY analogs
KR20010052587A (ko) 1998-06-08 2001-06-25 둘락 노먼 씨. 뉴로펩티드 ｙ5 수용체 길항제
SE9802080D0 (sv) 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
EP1306091A3 (en) 1998-07-31 2003-05-21 Novo Nordisk A/S Stimulation of beta cell proliferation
MY155270A (en) 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
CN1495198A (zh) 1998-12-07 2004-05-12 �о���Ӧ�ÿ�ѧЭ��ɷ����޹�˾ 胰高血糖素样肽-1的类似物
ATE309197T1 (de) 1999-02-05 2005-11-15 Emisphere Tech Inc Verfahren zur herstellung alkylierter salicylamide
ES2301477T3 (es) 1999-02-22 2008-07-01 Merrion Research I Limited Forma de dosificacion oral solida que contiene un potenciador.
AU3240900A (en) 1999-02-22 2000-09-04 Emisphere Holdings, Inc. Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
NZ514916A (en) 1999-04-30 2004-06-25 Amylin Pharmaceuticals Inc Exendins and exendin agonists linked to polyethylene glycol polymers
CA2363712C (en) 1999-05-17 2011-05-10 Conjuchem Inc. Long lasting insulinotropic peptides
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
GB9923436D0 (en) 1999-10-04 1999-12-08 American Home Prod Pharmaceutical compositions
US6793934B1 (en) 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form
US7262325B2 (en) 2000-06-02 2007-08-28 Emisphere Technologies, Inc. Method of preparing salicylamides
US7049283B2 (en) 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
PT1355942E (pt) 2000-12-07 2008-11-21 Lilly Co Eli Proteínas de fusão de glp-1
US7199217B2 (en) 2000-12-13 2007-04-03 Eli Lilly And Company Amidated glucagon-like peptide-1
EP2123293A3 (en) 2000-12-14 2010-09-08 Amylin Pharmaceuticals, Inc. Peptide YY and petide YY agonists for treatment of metabolic disorders
US6589938B2 (en) 2001-06-29 2003-07-08 National University Of Singapore Use of angiotensin I derivatives as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders
US20030068356A1 (en) 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
DE60228972D1 (de) 2001-07-31 2008-10-30 Us Gov Health & Human Serv Glp 1 exendin 4 peptidanaloga und deren verwendungen
HU228621B1 (en) 2001-09-24 2013-04-29 Univ Oregon Health & Science Modification of feeding behavior
WO2003045331A2 (en) 2001-11-29 2003-06-05 Emisphere Technologies, Inc. Formulations for oral administration of cromolyn sodium
US8058233B2 (en) 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
PL372394A1 (en) 2002-02-01 2005-07-25 Pfizer Products Inc. Dry granulated formulations of azithromycin
MXPA04008068A (es) 2002-02-20 2004-11-26 Lilly Co Eli Metodo para administrar moleculas de glp-1.
ATE432289T1 (de) 2002-07-04 2009-06-15 Zealand Pharma As Glp-1 und behandlungsmethode für diabetes
JP2004131398A (ja) 2002-10-08 2004-04-30 Taihei Chemical Industrial Co Ltd 錠剤用滑沢剤
EP2277527A3 (en) 2003-01-17 2011-08-31 Ipsen Pharma Peptide YY analogs
US20050059605A1 (en) 2003-01-31 2005-03-17 Krishna Peri Chemically modified metabolites of regulatory peptides and methods of producing and using same
EP1605897B1 (en) 2003-03-19 2012-07-25 Eli Lilly And Company Polyethelene glycol link glp-1 compounds
CA2525168A1 (en) 2003-05-14 2004-12-02 Emisphere Technologies, Inc. Compositions for delivering peptide yy and pyy agonists
US7572581B2 (en) 2003-06-30 2009-08-11 Roche Molecular Systems, Inc. 2′-terminator nucleotide-related methods and systems
CA2529604C (en) 2003-07-11 2012-05-08 Novartis Ag Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form
JP2007501812A (ja) 2003-08-08 2007-02-01 ノボ　ノルディスク　アクティーゼルスカブ ペプチドのための結合剤として新しい構造上十分に定義された枝分れしたポリマーの合成および適用
CN100444898C (zh) 2003-09-19 2008-12-24 诺沃挪第克公司 治疗肽的清蛋白结合型衍生物
KR101241862B1 (ko) 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 ｇｌｐ-1 유도체
JP2007537981A (ja) 2003-09-19 2007-12-27 ノボ　ノルディスク　アクティーゼルスカブ 新規の血漿タンパク質親和性タグ
BRPI0416743A (pt) 2003-11-20 2007-01-16 Novo Nordisk As formulação farmacêutica, e, métodos de preparar uma formulação de peptìdeo apropriada para uso em um dispositivo de injeção, para reduzir depósitos em equipamento de produção e no produto final, e para reduzir o entupimento de dispositivos de injeção por uma formulação de peptìdeo
BRPI0417717A (pt) 2003-12-18 2007-04-03 Novo Nordisk As composto, composição farmacêutica, e, uso de um composto
CA2550050A1 (en) 2003-12-18 2005-06-30 Novo Nordisk A/S Novel glp-1 analogues linked to albumin-like agents
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
EP1789440A4 (en) 2004-02-11 2008-03-12 Amylin Pharmaceuticals Inc REASONS FOR THE FAMILY OF PANCREATIC POLYPEPTIDES AND POLYPEPTIDES CONTAINING THEM
KR101427024B1 (ko) 2004-02-11 2014-08-05 아스트라제네카 파마수티컬스 엘피 선택가능한 특성을 갖는 하이브리드 폴리펩티드
BRPI0507585A (pt) 2004-03-17 2007-07-03 7Tm Pharmas As agonistas seletivos do receptor y2 para intervenções terapêuticas
WO2005089790A2 (en) 2004-03-17 2005-09-29 7Tm Pharma A/S Y2/y4 selective receptor agonists for therapeutic interventions
DK2060266T3 (da) 2004-03-17 2011-11-14 7Tm Pharma As Y4-selektiv receptoragonist PP2-36 til terapeutiske indgreb
CN101361967A (zh) 2004-03-17 2009-02-11 7Tm制药联合股份有限公司 用于治疗性干预的y2/y4选择性受体激动剂
WO2005099672A1 (en) 2004-04-13 2005-10-27 Ranbaxy Laboratories Limited A modified release pharmaceutical formulation comprising amoxicillin and clavulanate
AU2005240213B8 (en) 2004-05-06 2011-10-20 Emisphere Technologies, Inc. Crystalline polymorphic forms of monosodium n-[8-(2-hydroxybenzoyl)amino]caprylate
CA2564866A1 (en) 2004-05-06 2005-11-17 Emisphere Technologies, Inc. Solid dosage form of wetted heparin
US8273794B2 (en) * 2004-05-14 2012-09-25 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
WO2005121090A1 (en) 2004-06-02 2005-12-22 Abbott Laboratories Substituted piperidines that have antiangiogenic activity
CN101010339B (zh) 2004-07-02 2011-11-09 布里斯托尔-迈尔斯斯奎布公司 人类胰高血糖素样肽-1调节剂及它们在治疗糖尿病及相关病况中的用途
TW200611704A (en) 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
CA2572770A1 (en) 2004-07-08 2006-01-19 Novo-Nordisk A/S Polypeptide protracting tags comprising a tetrazole moiety
EP1791553B1 (en) 2004-07-12 2013-10-23 Emisphere Technologies, Inc. Compositions for delivering peptide yy and pyy agonists
US7994119B2 (en) 2004-07-19 2011-08-09 University Of Cincinnati Compounds for control of appetite
US20060078623A1 (en) 2004-08-13 2006-04-13 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
WO2006049681A2 (en) 2004-08-30 2006-05-11 Bayer Pharmaceuticals Corporation Selective neuropeptide y2 receptor agonists
US7893017B2 (en) 2004-10-07 2011-02-22 Novo Nordisk A/S Protracted GLP-1 compounds
WO2006037811A2 (en) 2004-10-07 2006-04-13 Novo Nordisk A/S Protracted exendin-4 compounds
EP1827780A4 (en) 2004-12-09 2007-12-12 Radial Corp Ltd MATERIAL HANDLING FOR RADIAL SAWS OF WOOD
US7410949B2 (en) 2005-01-18 2008-08-12 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
US20080153779A1 (en) 2005-02-01 2008-06-26 Jun Liao Gastric Retention and Controlled Release Delivery System
US8067362B2 (en) 2005-02-02 2011-11-29 Novo Nordisk As Insulin derivatives
EP1858546A4 (en) 2005-03-04 2009-03-04 Biorexis Pharmaceutical Corp MODIFIED TRANSFERRINFUSION PROTEINS
GB0504857D0 (en) 2005-03-09 2005-04-13 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
AU2006224537A1 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Extended GLP-1 compounds
WO2006097535A2 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Peptide agonists of the glucagon family with secretin like activity
US20090062192A1 (en) 2005-03-18 2009-03-05 Novo Nordisk A/S Dimeric Peptide Agonists of the Glp-1 Receptor
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
US20080260818A1 (en) 2005-03-28 2008-10-23 Dexcel Pharma Technologies Ltd. Controlled Absorption of Statins in the Intestine
EP1883652A2 (en) 2005-05-26 2008-02-06 Bristol-Myers Squibb Company N-terminally modified glp-1 receptor modulators
WO2007008778A2 (en) 2005-07-11 2007-01-18 Nastech Pharmaceutical Company Inc. Formulations for enhanced mucosal delivery of pyy
WO2007011958A2 (en) 2005-07-15 2007-01-25 Emisphere Technologies, Inc. Intraoral dosage forms of glucagon
BRPI0613984A2 (pt) 2005-07-18 2011-03-01 Novo Nordisk As peptìdios para uso no tratamento da obesidade, seu uso e composição farmacêutica compreendendo os mesmos
CN105056211A (zh) 2005-08-19 2015-11-18 安米林药品有限责任公司 治疗糖尿病和降低体重的毒蜥外泌肽
US20070049557A1 (en) 2005-08-24 2007-03-01 Hashim Ahmed Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
US8022035B2 (en) 2005-09-21 2011-09-20 7Tm Pharma A/S Y4 selective receptor agonists for therapeutic interventions
EP1934245B1 (en) 2005-09-21 2011-07-13 7TM Pharma A/S Y2 selective receptor agonists for therapeutic interventions
WO2007061434A2 (en) 2005-11-10 2007-05-31 Nastech Pharmaceutical Company Inc. A pharmaceutical formulation of glp-1 and its use for treating a metabolic syndrome
KR20140053419A (ko) 2005-11-17 2014-05-07 노파르티스 아게 약제학적 조성물
ES2381497T3 (es) 2005-12-07 2012-05-28 F. Hoffmann-La Roche Ag Agonistas del receptor del neuropéptido-2
WO2007067964A2 (en) 2005-12-08 2007-06-14 Nastech Pharmaceutical Company Inc. Mucosal delivery of stabilized formulations of exendin
EP1963343A1 (en) 2005-12-14 2008-09-03 Novo Nordisk A/S Polypeptide protracting tags
US20070197445A1 (en) 2006-01-18 2007-08-23 University Of Cincinnati Compounds for control of appetite
US20090186817A1 (en) 2006-03-21 2009-07-23 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of using same
CA2648594C (en) 2006-04-07 2012-10-16 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US8927015B2 (en) 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
EP2386572B1 (en) 2006-05-09 2015-07-08 Novo Nordisk A/S Insulin derivative
CA2654566A1 (en) 2006-06-09 2007-12-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
EP2040718B1 (en) 2006-06-28 2017-12-27 Emisphere Technologies, Inc. Gallium nitrate formulations
GB0613196D0 (en) 2006-07-03 2006-08-09 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
ES2296529B1 (es) 2006-08-07 2009-04-01 Laboratorios Farmaceuticos Rovi, S.A. Composicion farmaceutica con promotores de absorcion.
WO2008023050A1 (en) 2006-08-25 2008-02-28 Novo Nordisk A/S Acylated exendin-4 compounds
US10875826B2 (en) 2006-09-07 2020-12-29 Emisphere Technologies, Inc. Process for the manufacture of SNAC (salcaprozate sodium)
PE20121528A1 (es) 2006-09-13 2012-12-12 Smithkline Beecham Corp Metodos para administrar agentes hipoglucemiantes de larga duracion
WO2008039351A2 (en) 2006-09-22 2008-04-03 Novartis Ag Method of manufacturing tablets containing pharmacologically active agents
GB0621973D0 (en) 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
US20100069410A1 (en) 2006-12-01 2010-03-18 Emisphere Technologies Inc. acyclovir formulations
US20090099074A1 (en) 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
US20100016237A1 (en) 2007-01-18 2010-01-21 Novo Nordisk A/S Novel Peptides for Use in the Treatment of Obesity
WO2008087190A2 (en) 2007-01-18 2008-07-24 Novo Nordisk A/S Use of peptides in combination with surgical intervention for the treatment of obesity
AU2008223108B2 (en) 2007-03-02 2013-10-10 Novartis Ag Oral administration of a calcitonin
GB0708226D0 (en) 2007-04-27 2007-06-06 7Tm Pharma As Y-receptor agonists
JP2011504871A (ja) 2007-06-01 2011-02-17 ノボ・ノルデイスク・エー／エス 固体又は半固体担体中にペプチド薬剤を含む自然に分散可能なプレコンセントレイト
WO2008154619A1 (en) 2007-06-12 2008-12-18 Smithkline Beecham Corporation Methods for detecting protein in plasma
BRPI0814629A2 (pt) 2007-07-09 2015-01-27 Imp Innovations Ltd Compostos e seus efeitos sobre o comportamento alimentar
WO2009032749A2 (en) 2007-08-29 2009-03-12 The Regents Of The University Of Californina Salicylanilide modified peptides for use as oral therapeutics
WO2009030774A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Truncated glp-1 derivatives and their therapeutical use
CN101842109B (zh) 2007-09-05 2014-01-29 诺沃-诺迪斯克有限公司 用a-b-c-d-衍生的肽和它们的治疗用途
EP2679597A1 (en) 2007-09-05 2014-01-01 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
WO2009040019A2 (en) 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
EP2195034A2 (en) 2007-09-27 2010-06-16 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of making and using same
MX2010003979A (es) 2007-10-16 2010-06-02 Biocon Ltd Composicion farmaceutica oralmente administrable y proceso para su preparacion.
AU2008318423B2 (en) 2007-11-02 2013-12-05 Emisphere Technologies, Inc. Method of treating vitamin B12 deficiency
US20090124639A1 (en) 2007-11-06 2009-05-14 Emisphere Technologies Inc. valacyclovir formulations
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
JP2011520847A (ja) 2008-05-16 2011-07-21 ノボ・ノルデイスク・エー／エス 遅効型ｙ２及び／又はｙ４レセプターアゴニスト
US9186412B2 (en) 2008-08-18 2015-11-17 Entera Bio Ltd. Methods and compositions for oral administration of insulin
ES2561208T3 (es) 2008-09-12 2016-02-25 Novo Nordisk A/S Método de acilación de un péptido o una proteína
US8299023B2 (en) 2008-09-17 2012-10-30 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists
GB0817067D0 (en) 2008-09-18 2008-10-22 7Tm Pharma As Intestinal treatment
PT2386203E (pt) 2008-10-15 2014-02-17 Bayer Cropscience Ag Utilização de ditiina-tetracarboximidas para combater fungos fitopatogénicos
BRPI0921230A2 (pt) 2008-11-05 2018-10-30 Hoffmann La Roche agonistas de receptor de neuropeptídeos-2 (y-2r) e usos dos mesmo.
CN101463081B (zh) 2009-01-12 2012-07-04 华东师范大学 一种glp-1衍生物
KR20110115582A (ko) * 2009-02-13 2011-10-21 베링거 인겔하임 인터내셔날 게엠베하 Ｄｐｐ－４ 억제제(리나글립틴)을 임의로 다른 당뇨병 치료제와 병용하여 포함하는 당뇨병 치료 약제
KR101413051B1 (ko) 2009-02-20 2014-07-31 입센 파마 에스.에이.에스 뉴로펩타이드 ｙ 수용체 결합성 화합물을 포함하는 세포독성 접합체
ITRM20090347A1 (it) 2009-07-03 2011-01-04 Univ Siena Dispositivo di analisi del sistema nervoso centrale attraverso l applicazione di stimoli di diversa natura combinati tra loro e lo studio delle corrispondenti reazioni.
AR077956A1 (es) 2009-09-14 2011-10-05 Bayer Cropscience Ag Combinaciones de compuestos activos
WO2011033068A1 (en) 2009-09-18 2011-03-24 Novo Nordisk A/S Long-acting y2 receptor agonists
JP2013507414A (ja) 2009-10-13 2013-03-04 エフ．ホフマン−ラ ロシュ アーゲー 神経ペプチド−２受容体（ｙ−２ｒ）アゴニスト
CN102905722A (zh) 2009-11-13 2013-01-30 诺沃—诺迪斯克有限公司 长效y2受体激动剂
CN111560060A (zh) 2009-12-16 2020-08-21 诺沃—诺迪斯克有限公司 双酰化glp-1衍生物
AU2010339907A1 (en) 2009-12-16 2012-07-05 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
US20110182985A1 (en) 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011109787A1 (en) 2010-03-05 2011-09-09 Conjuchem, Llc Methods of administering insulinotropic peptides
US20110311621A1 (en) 2010-03-16 2011-12-22 Paul Salama Pharmaceutical compositions and methods of delvery
WO2011131646A1 (en) 2010-04-20 2011-10-27 Novo Nordisk A/S Long-acting gastrin derivatives
WO2011136361A1 (ja) 2010-04-30 2011-11-03 株式会社 三和化学研究所 生理活性物質等の生体内安定性向上のためのペプチド及び生体内安定性が向上した生理活性物質
US9186392B2 (en) 2010-05-05 2015-11-17 Boehringer Ingelheim International Gmbh Combination therapy
DE202010015867U1 (de) 2010-11-25 2011-05-05 Buchhalter, Thomas Elektromechanische Halterung zur Aufnahme von Navigations- und Kommunikationsgeräte im KFZ
RU2600440C3 (ru) 2010-12-16 2021-12-10 Ново Нордиск А/С Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
GB201101459D0 (en) 2011-01-27 2011-03-16 Imp Innovations Ltd Novel compounds and thier effects on fedding behaviour
KR101972836B1 (ko) 2011-04-12 2019-04-29 노보 노르디스크 에이/에스 이중 아실화된 ｇｌｐ-1 유도체
EP2729481B1 (en) 2011-07-08 2018-10-17 Amylin Pharmaceuticals, LLC Engineered polypeptides having enhanced duration of action with reduced immunogenicity
HUE062740T2 (hu) 2012-03-22 2023-12-28 Novo Nordisk As GLP-1 peptidek készítményei és elõállításuk
ES2715308T3 (es) 2012-03-22 2019-06-03 Novo Nordisk As Composiciones que comprenden un agente de suministro y su preparación
EP2827845B1 (en) 2012-03-22 2018-12-26 Novo Nordisk A/S Compositions comprising a delivery agent and preparation thereof
EP2855517A1 (en) 2012-05-29 2015-04-08 Novo Nordisk A/S Pancreatic polypeptide compounds and use
JP6517690B2 (ja) 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
PL2866825T3 (pl) 2012-07-01 2021-02-22 Novo Nordisk A/S <div>ZASTOSOWANIE PEPTYDÓW GLP-1 O PRZEDŁUŻONYM DZIAŁANIU</div>
BR112015027528B1 (pt) 2013-05-02 2023-02-14 Glaxosmithkline Intellectual Property Development Limited Polipeptídeo, forma de sal, combinação farmacêutica e composição farmacêutica
CA2910903A1 (en) 2013-05-02 2014-11-06 Novo Nordisk A/S Oral dosing of glp-1 compounds
WO2015071356A1 (en) 2013-11-15 2015-05-21 Novo Nordisk A/S Hpyy(1 -36) having a beta-homoarginine substitution at position 35
KR20160075819A (ko) 2013-11-15 2016-06-29 노보 노르디스크 에이/에스 선택적 pyy 화합물 및 그것의 사용
WO2016128972A1 (en) 2015-02-09 2016-08-18 Entera Bio Ltd. Formulations for oral administration of active agents with controlled absorption profile
JP6731958B2 (ja) 2015-06-12 2020-07-29 ノヴォ ノルディスク アー／エス 選択的ｐｙｙ化合物及びその使用
US10905744B2 (en) 2015-10-07 2021-02-02 Cyprumed Gmbh Pharmaceutical formulations for the oral delivery of peptide drugs
EP4299118A3 (en) 2018-02-02 2024-04-10 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant

Also Published As

Publication number Publication date
EP3730127A1 (en) 2020-10-28
EP2651398B1 (en) 2017-12-13
LT2651398T (lt) 2018-03-26
US20210177944A1 (en) 2021-06-17
JP2016117759A (ja) 2016-06-30
US10086047B2 (en) 2018-10-02
PL2651398T3 (pl) 2018-05-30
MX2013006171A (es) 2013-07-15
EP3326620A1 (en) 2018-05-30
DK3326620T3 (da) 2020-05-25
KR20140030116A (ko) 2014-03-11
EP3326620B1 (en) 2020-03-04
BR112013014942B1 (pt) 2020-01-28
PT2651398T (pt) 2018-03-09
MX345501B (es) 2017-02-02
RS60321B1 (sr) 2020-07-31
RU2013131913A (ru) 2015-01-27
CN103260608A (zh) 2013-08-21
CN105963685B (zh) 2021-01-15
US20230302092A1 (en) 2023-09-28
DK2651398T3 (en) 2018-03-12
RU2600440C2 (ru) 2016-10-20
US20180360918A1 (en) 2018-12-20
CN105963685A (zh) 2016-09-28
SMT201800117T1 (it) 2018-05-02
RU2600440C3 (ru) 2021-12-10
AU2011343190B2 (en) 2016-12-08
US9278123B2 (en) 2016-03-08
SI3326620T1 (sl) 2020-07-31
HRP20180425T1 (hr) 2018-04-20
BR112013014942A2 (pt) 2017-05-30
US20220313786A1 (en) 2022-10-06
ES2661676T3 (es) 2018-04-03
KR101925620B1 (ko) 2018-12-05
US20130345134A1 (en) 2013-12-26
RS56998B1 (sr) 2018-05-31
EP2651398A1 (en) 2013-10-23
AU2011343190A1 (en) 2013-06-06
WO2012080471A1 (en) 2012-06-21
JP5902194B2 (ja) 2016-04-13
CA2821886A1 (en) 2012-06-21
HUE036066T2 (hu) 2018-06-28
US10960052B2 (en) 2021-03-30
US20160151462A1 (en) 2016-06-02
MX377589B (es) 2025-03-10
US20240277817A1 (en) 2024-08-22
JP2014503526A (ja) 2014-02-13
PL3326620T3 (pl) 2020-08-24
US11382957B2 (en) 2022-07-12

Similar Documents

Publication Publication Date Title
SI2651398T1 (en) SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS
WO2012065963A3 (en) Antiviral condensed heterocyclic compounds
MX2012007410A (es) Compuestos antivirales novedosos.
UA96964C2 (ru) Соединения полициклической мочевины с антибактериальными свойствами
JO2973B1 (en) Fumarate salt for (alpha-beta-R) -6-bromo-alpha-[2- (methylamino) ethyl-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinoline ethanol
RU2015147876A (ru) Пероральная дозированная форма соединений глюкагоноподобного пептида-1
UA109010C2 (en) Morpholino pyrividines and their use in therapy
SG171649A1 (en) Dpp iv inhibitor formulations
UA104021C2 (ru) ПРОИЗВОДНЫЕ ТИЕНО[2,3-b]ПИРИДИНА КАК ИНГИБИТОРЫ РЕПЛИКАЦИИ ВИРУСА
UA103332C2 (ru) Фармацевтическая композиция, которая содержит непептидный активный агент с первичной или вторичной аминогруппой
MY174002A (en) Combination theraphy for the treatment of diabetes
SI2582683T1 (en) Treatment of gout and hyperuricemia
PE20081578A1 (es) Formulacion en polvo de valganciclovir
WO2008020227A3 (en) Antibacterial pyrrolecarboxamides
HRP20250102T1 (hr) Pth spojevi s kontroliranim oslobađanjem
SI2576524T1 (en) USE OF METFORMIN IN COMBINATION WITH GLUCOIN-ACTIVE ACTIVATORS, ALSO THE COMPOSITION, COMPARING METFORMIN AND GLUCOIN-ACTIVE ACTUATOR
WO2012090225A3 (en) Novel cocrystals / molecular salts of metformin with oleoylethanolamide as an effective anti-diabetic + anti- obesity agent
WO2008074833A3 (en) Compounds
MA32406B1 (fr) Composés contenant de l&#39;azote tricyclique et utilisation de ceux-ci comme antibactériens
EA200901146A1 (ru) Твердые лекарственные формы, содержащие алискирен и его фармацевтически приемлемые соли
HRP20171742T4 (hr) 2,4,6-trifluor-n-[6-(1-metilpiperidin-4-karbonil)piridin-2-il]benzamid, namijenjen liječenju migrene oralnom ili intravenskom primjenom
GEP20135832B (en) Benzothiazines derivatives, preparation thereof, and their application as drugs
UA101407C2 (ru) Стабильная комбинированная фармацевтическая композиция амлодипина и бисопролола фумарат
MX2010006215A (es) Derivados de piperazina y su uso como moduladores del receptor de leptina.
MX2010006216A (es) Nuevos compuestos iii.